摘要
目的:探讨奥西替尼对比埃克替尼一线治疗表皮生长因子受体(EGFR)突变转移性非小细胞肺癌患者中的应用效果。方法:选择2018年1月~2019年1月诊断为晚期非小细胞肺癌(NSCLC)患者100例随机数字表法分为研究组和对照组各50例,对照组采用埃克替尼治疗,研究组采用奥西替尼一线治疗,定期随访患者治疗效果,比较两组治疗有效率、生活质量、不良反应、生存率(无进展生存率以及总生存率)。结果:研究组客观缓解率(ORR)60.00%与疾病控制率(DCR)82.00%均明显高于对照组的40.00%、64.00%,差异有统计学意义(P<0.05)。两组治疗4个疗程后生活质量提高明显,且研究组在情感状况、功能状况、附加关注情况、生理状况、社会/家庭状况评分均高于对照组,差异有统计学意义(P<0.05)。研究组恶心、食欲缺乏、腹泻、皮疹、贫血的发生率均明显低于对照组,差异有统计学意义(P<0.05),两组并发症发生率差异无统计学意义(P>0.05)。研究组随访25个月无进展生存率与总生存率高于对照组,差异有统计学意义(P<0.05)。研究组患者中位FPS为(15.38±1.95)个月、中位OS为(17.93±2.14)个月长于对照组的FPS(10.68±1.42)个月、中位OS(12.25±2.10)个月,差异有统计学意义(P<0.05)。结论:与埃克替尼相比,采用奥西替尼治疗EGFR突变转移性非小细胞肺癌的临床效果更为显著,不良反应总体发生率较低,无进展生存率及总生存率均较高,有助于提高患者生活质量。
Objective To investigate the efficacy of osimertinib versus icotinib in the first-line treatment of patients with epidermal growth factor receptor(EGFR)-mutated metastatic non-small cell lung cancer.Method A total of 100 patients with advanced non-small cell lung cancer(NSCLC)diagnosed from January 2018 to January 2019 were selected and randomly divided into study group and control group,50 cases in each group.The control group was treated with icotinib,and the study group was treated with osimertinib as first-line treatment.The treatment effect of patients was followed up regularly,and the effective rate,quality of life,toxic and side effects,and survival rate(progression-free survival rate and overall survival rate)were compared between the two groups.Results The objective response rate(ORR)of 60.00%and the disease control rate(DCR)of 82.00%in the study group were significantly higher than those in the control group 40.00%and 64.00%(P<0.05);the quality of life in the two groups improved significantly after 4 courses of treatment.The scores of physiological status,social/family status,emotional status,functional status,and additional concerns in the study group were higher than those in the control group(P<0.05);the incidences of nausea,anorexia,diarrhea,rash,and anemia in the study group were significantly lower than the control group(P<0.05),the incidence of complications in the two groups was not statistically significant(P>0.05).The 25-month follow-up rate of progression-free survival and overall survival in the study group was higher than that in the control group(P<0.05).The median FPS of the patients in the study group was(15.38±1.95)months and the median OS was(17.93±2.14)months longer than that of the control group,FPS was(10.68±1.42)months and the median OS was(12.25±2.10)months(P<0.05).Conclusion Compared with icotinib,the clinical efficacy of osimertinib in the treatment of EGFR-mutant metastatic non-small cell lung cancer is more significant,the overall incidence of adverse reactions is lower,an
作者
刘瑛
黄念
李秋波
LIU Ying;HUANG Nian;LI Qiu-bo(Oncology department,Jingmen First People's Hospital,Jingmen 448000,China)
出处
《吉林医学》
CAS
2023年第10期2843-2847,共5页
Jilin Medical Journal
基金
荆门市引导性科研计划项目[项目编号:2021YDKY090]。
